As confirmed by TDM monitoring,
removal of ritonavir can be safely attempted in patients with un-detectable HIV viral load and an unfavourable UGT1A1*28 geno-type without the risk of exposure to subtherapeutic plasma
atazanavir concentrations and subsequent virological failure.